Rapamune (sirolimus) Lawsuits
Last Updated: May 2008 • 2 Comments
Contact a Lawyer
Submit information about your potential case to be reviewed by an attorney.
Recent research suggests that Rapamune, also known as sirolimus, may increase the risk of diabetes after a kidney transplant. This is a serious health concern, and could lead to kidney transplant failure.
STATUS OF RAPAMUNE LAWSUITS: Studies are being reviewed by lawyers who are considering the potential for Rapamune litigation for those diagnosed with diabetes after a kidney transplant.
MANUFACTURER: Wyeth
OVERVIEW: Rapamune is the trade name for sirolimus, a relatively new immunosuppresant which is used to prevent the body from rejecting the organ after a transplant. It is primarily used following kidney transplants, and is particularly useful for those who required a transplant as a result of hemolytic-uremic syndrome, which can reoccur in the transplanted kidney.
In the July 2008 issue of the Journal of the American Society of Nephrology a study linked the user of sirolimus to an increased risk of new-onset diabetes. Researchers reviewed data for 20,000 Medicare patients who received a kidney transplant between 1995 and 2003. When compared to those who received another anti-rejection drug, the diabetes risk was between 36% and 66% higher among patients treated with sirolimus.
RAPAMUNE DIABETES SIDE EFFECTS: Diabetes is a serious health concern which can cause serious complications for kidney transplant patients. According to researcher, those who develop diabetes after a transplant have the same risk of transplant failure as a patient who develops acute transplant rejection.
The July 2008 report is the first large study which suggests a connection between Rapamune and diabetes. Prior animal studies and small clinical studies have suggested a sirolimus side effects may increase the risk of diabetes. Further research may be needed to clarify the risk of diabetes among kidney transplant patients treated with Rapamune.
Review a Potential Rapamune Lawsuit with an Attorney
As part of an ongoing review into the potential for Rapamune class action suits and individual lawsuits, attorneys are reviewing the circumstances surrounding kidney transplant patients who have been diagnosed with diabetes. For those who developed new-onset diabetes following use of Rapamune (sirolimus) after a kidney transplant, complete the information below and you may be contacted by a lawyer.
Pingback by Kidney Transplant Drug Rapamune (sirolimus) linked to Diabetes — AboutLawsuits.com on 30 May 2008:
[...] be published in the July issue of the Journal of the American Society of Nephrology indicates that Rapamune (sirolimus), an anti-rejection drug often given to kidney transplant patients, may increase the risk of [...]
Pingback by Rapamune Side Effects May Increase Risk of Death After Liver Transplant: FDA - AboutLawsuits.com on 15 June 2009:
[...] to transplant doctors that switching their patients to the anti-organ transplant rejection drug Rapamune after a liver transplant may increase the risk of [...]